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Genetics of Biliary Atresia: A 
Work in Progress for a Disease 
with an Unavoidable Sequela into 
Liver Cirrhosis following Failure 
of Hepatic Portoenterostomy
Consolato M. Sergi
Abstract
The bile duct development may not be fully completed at birth, and this is quite 
a common event. Moreover, bile formation is immature, and there is a propensity 
for the neonate to develop cholestasis in the presence of a wide variety of insults 
that can damage the liver. A biliary atresia is a correctable form of infantile cholan-
giopathies. The Kasai hepatic portoenterostomy (HPE) is often performed and is 
successful if it is done at an early stage. However, HPE can fail, and the liver fate is 
inevitably a cirrhotic change. Biliary atresia is heterogeneous and may result from a 
combination of genetic factors, vascular, infective or toxic insults with activation of 
different genetic and immunological pathways. In this chapter, we will review some 
genes that may be highly relevant to biliary atresia, including not only PKHD1, 
JAG1, and CFTR, but also GPC1, ADD3 and others. Four genetic loci are considered 
as predisposition loci in biliary atresia, despite the absence of an etiologic mutation. 
The rare occurrence of biliary atresia in well-known genetic syndromes seems to 
suggest coincidental finding, but epigenetic aspects might play a significant role in 
contributing to the increase of biliary atresia rate.
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1. Introduction
Biliary atresia (BA) is a necroinflammatory process of the intrahepatic (inside 
of the liver) and extrahepatic (outside of the liver) biliary system with a various 
etiologic background. Since the introduction of the yellow card registries in Taiwan 
in 2002 as a pilot study and then in other countries, the awareness and the proper 
management of this disease has increased. In the Western countries, BA occurs in 
about 1:18,000 live births, but the reported incidences vary from 5 to 32 per 105 
live births [1]. The incidence of BA is highest in Asia and in some countries of the 
Pacific region comparing to the rest of the world with male infants more often 
affected than females. The clinical triad includes neonatal jaundice (conjugated 
hyperbilirubinemia that is considered lasting beyond 2 weeks of postnatal life), 
acholic (pale) stools and dark urine, and hepatomegaly. The ultrasonography and 
Liver Cirrhosis - Debates and Current Challenges
2
the endoscopic retrograde cholangiopancreatography (ERCP) are essential to 
address the diagnosis, which relies on the microscopic examination. Histologically, 
BA relies on the inflammatory injury of the intra- and extrahepatic biliary tract 
with sclerosis, luminal narrowing, and final obliteration of the biliary tree. BA lead 
to liver cirrhosis, if no treatment is initiated. Also, death can occur within the 2 
years of life or first infancy. Although BA is, currently, not known to be hereditary, 
some families with recurrence of this disease have been reported in the literature. 
BA requires an immediate shunt to promote the discharge of bilirubin from the pro-
gressive accumulation in the liver and Professor Morlo Kasai (1922–2008) invented 
a technique (Kasai hepatic portoenterostomy or HPE), which is currently in use 
and the first line of surgical therapy for these patients [2–4]. Subsequently, a liver 
transplantation may be needed, particularly in infants who underwent to surgery 
not early in life as it should be. The delay of the surgical hepatic portoenterostomy 
is still a problem in some regions not only in underdeveloped countries, but even in 
USA and Canada. Thus, the awareness of this condition is crucial to save lives and 
money. Liver transplantation may be crucial needed to restore the flow of bile or if 
liver cirrhotic complications occur (Figure 1). Currently, nearly 90% of BA infants 
survive. The majority of these patients have normal quality of life. Prof. Kasai 
is considered one of the greatest innovators in the field of pediatric surgery and 
numerous thousands of babies and their families will be always grateful to him.
2. Bile duct development
The development of the biliary tree is crucial to understand and interpret the 
categories of neonatal and infantile cholangiopathies. This aspect is particularly 
important if the patient is a preterm baby or a baby considered small for gestational 
age [5]. At the 3rd week of the post-ovulatory period, endodermal cells sprout from 
the primitive foregut at the cranial portion. These cells grow towards a loosely 
arranged mesoderm. The direction is the plexus vitellinus of the embryo. Similarly, 
a bud arises caudally from the foregut and form the primordium (anlage) of the 
extrahepatic biliary system [5–8]. After a sub-massive and massive liver necrosis, a 
ductular reaction is observed in the survived liver tissue. This phenomenon is seen 
in individuals with fulminant hepatitis and endorses the theory recommending 
the presence of ordinary progenitor cells that may totally differentiate in bile duct 
epithelial cells, specifically along the portal vein branches [9]. At the hilum of the 
liver between the 6th and the 9th week of the postovulatory period, progenitor 
Figure 1. 
Biliary atresia with extensive fibrosis and bile duct proliferations (asterisk) (Hematoxylin and eosin staining, 
x100 original magnification).
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cells, which are in contact with the mesenchyme that surrounds the primitive 
portal vein, form first a mono-layered and then later a double-layered cell cords 
harboring a “slit-like” lumen [5, 10]. This structure is the fundamental (primitive) 
intrahepatic biliary structure, which has been labeled (bilaminar) “ductal plate.” 
At the 12th week of intrauterine gestation and on, a continuous remodeling of this 
prototypic structure takes place. A few parts of the primitive biliary structures 
dilate and slightly roam toward the center of the portal field. These structures are 
called “peripheral tubular or ductular structures.” These biliary structures are the 
immature form of the interlobular bile ducts. Subsequently, one or two immature 
structures, mostly peripherally located ductular structures transmute into mature 
interlobular bile ducts. In the meantime, most of these peripherally located struc-
tures will gradually disappear, and an essential contribution to this process is due 
to the apoptosis, which was initially hypothesized by Professor Valeer Desmet 
(Leuven, Belgium) as early as 1985 [11–16]. Subsequently, Meckel syndrome, a 
genetic syndrome with autosomal recessive inheritance, occipital encephalocele, 
postaxial polydactyly, diffuse cystic renal dysplasia, and malformation of the 
orthologue development of the ductal plate of the liver, was targeted by my research 
group in the late years of last century [17]. The malformed ductal plates in the fetal 
livers with Meckel syndrome showed a marked decrease in the apoptotic rate and 
Fas expression, a pro-apoptotic marker, and an increase in proliferative activity and 
expression of Bcl-2, which has an antiapoptotic significance [18]. The conversion 
of the ductal plate into mature and bile draining interlobular bile ducts is conveyed 
by the appearance of specific intermediate filaments of the cytoskeleton or keratins 
or cytokeratins (CKs) [19, 20]. The epithelial cells that are forming the interlobular 
bile ducts start expressing K-7 and K-19 in addition to K-8 and K-18. The keratins 
K-8 and K-18 are positive in normal hepatocytes of the adult. Quantification of 
structures of the biliary system and their maturity may be beneficial in the assess-
ment of the maturation of the intrahepatic biliary tree in neonatal and infantile 
cholangiopathies, and the lack of an interlobular bile duct is the most worrisome 
prognosticator in a cholangiopathy independently from the specific etiology or 
Figure 2. 
Keratin 7-immunostaining of the biliary proliferating neoductules (Anti-cytokeratin 7 immunostaining, 
Avidin-Biotin-Complex, x100 original magnification).
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labeling of the disease [21]. Figure 2 shows the immunohistochemical staining of 
the biliary proliferation using an antibody against cytokeratin 7.
3. Liver biopsy
Currently, the liver biopsy remains the gold standard for determining the 
diagnosis of surgical conditions with neonatal cholestasis, such as BA, which is the 
most critical surgically correctable form of persistent conjugated hyperbilirubine-
mia. There is an incredible rate of accuracy that comes with the experience of the 
pathologist and liver biopsy is precise in probably more than 9 cases out of 10, in 
most tertiary centers of pediatric healthcare, provided that the liver tissue encom-
passes at least six portal tracts. The experience of the pathologist may be crucial to 
address the patient to a pediatric surgeon or genetic counseling for neonatal cho-
lestatic liver diseases. The challenge may be quite high that some argued that there 
might be a continuum with a single underlying cause. According to our previously 
published data [21], patterns of ductular reactions may muddle the pathologist, and 
ductal plate remnants, often seen in the liver histology, may indeed recapitulate the 
embryonic anlage. As a pediatrician and pathologist, the urgency of critical reports 
is well understood [22]. Medical and surgical causes of neonatal cholestasis need to 
be ruled out promptly. The central differential diagnoses of BA that need to be kept 
in mind are: Alagille syndrome, alpha-1-antitrypsin deficiency, cystic fibrosis, scle-
rosing cholangitis with neonatal onset, and more rarely progressive familial intra-
hepatic cholestasis (PFIC) types I-III. The differential diagnosis may be complicated 
and ancillary studies may need mass spectroscopy or other sophisticated techniques.
4. Genetics
As indicated early, BA is usually not hereditary, but some cases and families 
with recurrence rate have been observed [23]. Four genetic loci are considered as 
predisposition loci in BA, although no etiologic mutation was identified. The rare 
occurrence of BA in well-known genetic syndromes seems to suggest coinciden-
tal finding, but epigenetic aspects might play a major role in contributing to the 
increase of BA rate. Chromosomal alterations reported in patients with BA include 
duplication, deletion, and single copy number variation. Duplications include 
trisomy 18, trisomy or tetrasomy 22, trisomy 21, trisomy 10q and trisomy 11q23. In 
trisomy 18, BA has been associated in individuals with congenital heart disease and 
facial dysmorphism. In trisomy or tetrasomy 22, cat eye syndrome occurs. Facial 
dysmorphism, congenital heart disease, and cleft palate occurred in trisomy 11q23, 
while coarctation of the aorta, anal anteposition, and mental retardation have been 
recorded in patients harboring trisomy 10q. Patients with trisomy 21 syndrome 
(Down syndrome) showed accompanying atresia of the duodenum and esophagus 
as well as a heterotaxic setting, which is a condition in which the internal organs are 
abnormally arranged in the abdomen and chest. Deletion of chromosomal portions 
has been identified on 18p, 2q73.3, 18q21, 17q12, 1p36, and 20p11.21. Facial dysmor-
phism, mental retardation, hypothyroidism, and polysplenia were founds in deletion 
of the 2q37.2, while hyperechogenic kidney and pancreatic hypoplasia were found in 
the deletion of 17q12. Facial dysmorphism and classic Pitt-Hopkins syndrome were 
found in the deletion of 1p36 and 18q21, respectively. Laterality defects and panhy-
popituitarism were findings in the setting of deletion of 20p11.21. Pitt-Hopkins syn-
drome is a condition characterized by developmental delay and intellectual disability 
with individuals with breathing problems, recurrent seizures, and distinctive facial 
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features [24–27]. There is a delay in the development of mental and motor skills with 
numerous affected individuals having features of autistic spectrum disorders. Copy 
number variations (CNVs) are defined as a type of structural variation: specifically, 
i.e., a type of duplication or deletion event that affects a considerable number of 
base pairs. CNVs are a phenomenon in which sections of the genome are repeated, 
and the number of repeats in the genome varies between individuals in the human 
population with a specific neurological disorder as seen in Huntington’s disease. In 
this disease, CAG (i.e., cytosine-adenine-guanine) repeats of less than 26 have no 
effect, but between 27 and 35 there is a risk for the offspring, 36–29 CAG repeats 
may (or may not) be affected by the disease but harbors 50% of risk to offspring, 
while 40 or more has a consequence with full penetrance of the disease and a risk of 
50% to offspring. CMVs have been identified in a cohort of patients with BA with 29 
specific CNVs involving the JAG1 gene and immunity-related genes. Genome-wide 
association studies performed in patients affected with BA identified four loci, of 
which one is in the Han population and three in Caucasians. In the Han ethnics of 
China, noncoding single nucleotide polymorphisms (SNPs) have been localized 
to ADD3 and XPNPEP1 genes. Noncoding SNPs and a heterozygous deletion have 
been localized in ARF6, EFEMP1, and GPC1 genes, respectively [28–30]. There 
have been some case reports of BA associated with identified mutation or diagnosed 
syndrome. The gene SERPINA1 was considered an aggravating factor for BA, and 
JAG1 was questioned in a few patients [31–34]. A compound heterozygous (one 
copy each of two different alleles) mutation was also questioned in case of PKHD1 
gene [35]. A heterozygous mutation of the gene MYO5B was found in a patient 
suffering from microvillus inclusion disease and progressive familial cholestasis 
[34]. The Dubin-Johnson syndrome was also found in a patient with BA implying 
the gene ABCC2 [34]. Progressive familial cholestasis without microvillus inclu-
sion disease was found in a patient with BA as well. The gene involved ABCB11 
harbored a heterozygous mutation. Heterozygous and hemizygous mutations of the 
genes CFC1 and ZIC3 were found in patients with laterality defects [36, 37]. To be 
hemizygous for a gene means to have only one copy of one allele of that gene. The 
Fumarase gene was seen in a patient having a homozygous mutation [38]. The gene 
GATA3 was involved as a heterozygous mutation in a patient with HDR syndrome 
(hypoparathyroidism, sensorineural deafness and renal abnormalities) [39], while 
the gene FGFR3 was involved in a patient with achondroplasia [40]. The Mitchell-
Riley syndrome was found in an individual with BA and a homozygous mutation 
of the gene RFX6 [41]. Fanconi anemia and BA with a biallelic mutation on ERCC4 
were also found [42]. Kartagener syndrome and BA also occurred in the literature 
[43]. The Zimmermann-Laband syndrome was present in an individual with BA and 
a heterozygous mutation of KCNH1 [44]. Kabuki syndrome and BA also occurred 
in the literature [45, 46]. The Mowat-Wilson syndrome was found in a patient with 
BA and a heterozygous deletion in the ZEB2 gene. Two more genes were also seen 
having a heterozygous mutation in patients with BA including UGT1A1 and MLL2 
[34]. Finally, three multiple congenital anomaly syndromes have been reported with 
BA, including Mutchinick syndrome, Goldenhar syndrome, and caudal regression 
syndrome. Although the presentation of case reports and small case series may 
indicate a genetic background suggesting that a genetic element plays a significant 
role in the pathogenesis of BA, we need to argue that the genetics is probably only 
one of the multiple factors that may occur coincidentally or sequentially. The few 
reported familial cases of BA have been supportive [46–50] although conflicting sets 
of monozygotic twins have also been identified [51–53]. Another important aspect 
is the variations in the incidence of BA among different ethnics and the incidence of 
HLA B12 and, of course, haplotypes A9-B5 and A28-B35 were also found to be higher 
in infants with BA compared to a control group [54]. The high incidence rates of BA 
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in some areas of Southeast Asia, as well as Polynesia, are evocative of an inherited 
predisposition, although a local eating style or viral factor cannot be rules out [51].
The original dichotomic description of BA in embryonic and fetal type or 
syndromic and non-syndromic forms is still valid [47]. The reader may need to keep 
in mind that most probably the term “atresia” is a misnomer and a necroinflamma-
tory process of obliterative nature is different from an atretic process in origin from 
the embryologic point of view. In consideration of the period in which “atresia” 
occurs, it may be classified as embryonic or fetal and perinatal. In approximately 
20% of patients with BA, the embryonic form is responsible, while the rest is due to 
fetal form, which is also called perinatal form. In the early form, the extrahepatic 
biliary tree might have undergone abnormal morphogenetic processes. BA patients 
suffering from this form of BA have associated non-hepatic structural anomalies, 
of which the most common multiple congenital anomalies is the polysplenia 
syndrome, which is found in 8–12% of patients with BA. This syndrome is char-
acterized by polysplenia/asplenia associated with cardiac defects (dextrocardia, 
tetralogy of Fallot, anomalies of the pulmonary vasculature, atrio-/ventricular 
septal defects) a midline liver, preduodenal portal vein, interruption of the inferior 
vena cava, and situs viscerum inversus, and intestinal malrotation. Other congenital 
malformations can be detected, such as cardiac anomalies, annular pancreas, immo-
tile cilia syndrome (pointing to Kartagener syndrome), duodenal atresia (leading 
to trisomy 21 syndrome), esophageal atresia, polycystic kidney disease, cleft palate, 
and jejunal atresia. The fetal or perinatal form is characterized by patency of the 
extrahepatic and intrahepatic biliary system at birth, but an inflammatory and 
sclerosing reaction, caused by perinatal injury, results in the obstruction of the 
biliary tree. The fetal or perinatal form accounts for four out five cases of BA, and it 
is not typically associated with congenital anomalies [48, 49].
If about 10% of patients with BA have multiple congenital anomalies, it has 
been argued that the laterality defects have a phenotype like that detected in the 
ciliopathies, which is a heterogeneous group of disorders caused by structural 
and functional abnormalities in genes that encode cilia proteins [23, 50–55]. 
Embryologically, cilia are evolutionarily conserved. The cilia support in founding 
the left-right axis in vertebrates and are present on numerous cell types. The cilia 
are also present in the apical surface of biliary cells or cholangiocytes. In these cells, 
cilium function is integral to bile flow, bile ductular maturation, and neoductular 
formation [49]. The PKHD1 gene is responsible for the autosomal recessive polycys-
tic kidney disease (ARPKD). The expression of the PKHD1 is polycystin, which was 
found reduced in the livers of infants with BA with and without associated renal 
cysts by comparing with liver resections of patients without BA [25, 46]. Studies 
involving rhesus rotavirus murine models of BA have found the extensive loss of 
primary cilia from extrahepatic cholangiocytes, which was verified by the finding 
of decreased ciliation in extrahepatic biliary ducts in infants with BA of perinatal 
type, although cilia appeared normal in neighboring peribiliary glands [50].
There is quite an overwhelming evidence against a Mendelian paradigm of 
inheritance of BA. The argument against a Mendelian inheritance is supported by 
the lack of familial penetrance, despite rare cases of familial BA [52, 53], and discor-
dant presentation of BA among twins, including monozygotic twins [54–57]. On the 
other side, a growing principle of developmental diseases exhibits unusual patterns 
of inheritance, including Bardet-Biedl syndrome. The Bardet-Biedl syndrome is a 
ciliopathy, which is clinically heterogeneous and specifically marked by oligogenic 
inheritance. The mutations in multiple genes cooperate to generate the phenotype 
of Bardet-Biedl syndrome. It has been suggested that a similar singularity related to 
gene-gene interactions, or epistasis, may account for the diversity of presentations in 
BA [23]. Non-Mendelian inheritance is also detected in Alagille syndrome, which is the 
7Genetics of Biliary Atresia: A Work in Progress for a Disease with an Unavoidable Sequela…
DOI: http://dx.doi.org/10.5772/intechopen.85071
result of a haploid insufficiency of JAG1 (alternatively its receptor NOTCH2). There is 
a inconstant intrafamilial clinical presentation [58, 59].  
Microchimerism is clearly defined as the occurrence of two genetically different cell 
populations in the same person. There are a few etiologies, in which it can arise and 
include blood transfusion, organ transplantation and the bidirectional transfer of cells 
between mother and fetus during pregnancy as well as the twin-to-twin transfer in 
utero [56]. Microchimerism has been suggested to explain the phenotypic heterogene-
ity and nonclassical genetic inheritance of BA [60, 61].
Recently, genome-wide association studies (GWASs) have been milestones in 
identifying some genes and pathways of several diseases. A GWAS is an obser-
vational study of a genome-wide set of genetic variants in diverse individuals to 
understand if any modification is associated with a trait. Generally, GWASs empha-
size the associations between single-nucleotide polymorphisms (SNPs) and traits 
like major human diseases but can equally be useful for any other genetic variants 
and any other organisms. SNPs are DNA sequence variations occurring probably 
1 in every 100, 200–300 bases along the 3-billion-base human genomic sequence 
and at least 1% of the population. SNPs make up about 90% of DNA sequence 
variation as indicated by the Human Genome Project (http://www.ornl.gov, http://
linkage.rockefeller.edu/soft/). On the other side, if one of the possible sequences is 
present in less than 1% of the population (99.9% of people have a C, and 0.1% have 
a G), then the variation is called a mutation [57, 58].
The Han Chinese population is particularly susceptible to GWAS because of the 
large size of individuals and homogeneity of this population. A recent study using 
a GWAS found a potential susceptibility locus for BA between the genes ADD3 and 
XPNPEP1 located with the chromosomal localization of 10q25.1 with replication in 
independent Chinese and Thai specimens and identification of BA in a Zebrafish 
model [59–61]. Interestingly, sequencing of a Han Chinese sample identified that 
a 5-SNP risk haplotype to be associated with BA and the genotype correlated with 
reduced levels of ADD3 expression [61]. The study was attempted to be replicated 
in a Caucasian cohort [60]. The authors found a stronger signal in the first intron 
of ADD3, although the exact genotype at this SNP was not predictive of the degree 
of ADD3 expression. The gene under intense investigation is ADD3 or adducin 3. 
Adducins are heteromeric proteins constituted of different subunits (alpha, beta, 
and gamma). The three subunits are involved in the assembly of the spectrin-actin 
network in red blood cells and at sites of cell-cell contact in epithelial tissues. 
Adducins alpha and gamma are universally expressed, while adducin beta is found 
in the brain and hematopoietic tissues. Adducin 3 is a cytoskeleton-associated 
protein that endorses the assemblage of the spectrin-actin network. Adducin 3 plays 
a role in actin filament capping and binds to calmodulin [62–63]. In Figure 3, the 
interaction of adducin 3 with other markers is depicted. This representation is the 
product of the interaction of several molecules, including ADD1, ADD2, ANKRD29, 
C1orf85, DDX10, MSANTD1, PSIP1, XPNPEP1, and XP07 [64]. Apart of adducin 1 
and 2 that belong to the same family of adducins (heteromeric cytoskeletal pro-
teins), the other genes/proteins are extremely intriguing to study in BA patients and 
may give us hints to understand the pathogenesis of this challenging cholangiopathy 
[65]. ANKRD29 (Ankyrin Repeat Domain 29) is a protein-coding gene with the 
gene located on chromosome 18q11.2. C1orf85 is a glycosylated lysosomal mem-
brane protein with gene ontology annotations including DNA binding transcription 
factor activity and, of course, ligand-dependent nuclear receptor transcription 
coactivator activity. DDX10 is a DEAD box protein, characterized by the conserved 
motif Asp-Glu-Ala-Asp (DEAD). This class of proteins are putative RNA helicases 
and are implicated in many cellular processes involving alteration of RNA second-
ary structure (e.g., translation initiation, nuclear and mitochondrial splicing, 
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and ribosome and spliceosome assembly). In consideration of the distribution 
patterns, some members of this family are held to be involved in embryogenesis. 
They may play a role in spermatogenesis, and, overall, cellular growth and division. 
MSANTD1 is Myb/SANT DNA Binding Domain Containing 1 and is a protein-
coding gene, which is also known as chromosome 4 open reading frame 44. PSIP1 
is PC4 and SFRS1 Interacting Protein 1, which is a protein-coding gene. PSIP1 is 
a transcriptional coactivator involved in the differentiation and neurogenesis of 
neuroepithelial stem cells and specifically in gene regulation and stress responses of 
lens epithelial cells. The shielding role during stress-induced apoptosis may raise the 
suspicion that this pattern may be particularly relevant to investigate in the future. 
Diseases associated with PSIP1 include atopic dermatitis. PSIP1 also seems interest-
ing because two related pathways with PSIP1 are ERK Signaling and Akt Signaling. 
XPNPEP1 is a protein coded from a gene XPNPEP1. The XPNPEP1 gene encodes 
the form in cytosol of a metalloaminopeptidase that catalyzes the cleavage of the 
N-terminal amino acid adjacent to a proline residue. It seems that this gene product 
plays a role in the degradation and maturation of tachykinins, neuropeptides, and 
peptide hormones. There are multiple transcript variants linked to alternative splic-
ing. Finally, XPO7 or Exportin 7 is coded by the XPO7 gene. The protein has binding 
and nuclear export signal receptor activity. It serves for the transport of protein 
and large RNAs through the nuclear pore complexes in an energy-dependent and 
regulated process. XPO7 mediates the nuclear export of proteins (cargos), which 
have broad substrate specificity. In the nucleus, this protein binds cooperatively to 
its cargo and the GTPase Ran in its active GTP-bound form. After curbing of this 
trimeric complex to the nuclear pore complex through binding to nucleoporins, 
EXPO7 translocated into the cytoplasm, and the disassembling of the complex and 
Figure 3. 
Interactome of the ADD3 protein with splice isoforms or post-translational modifications are collapsed, while 
each node represents all the proteins produced by a single, protein-coding gene locus. The edges represent 
protein-protein interactions with different color according to the interaction type. A red line indicates the 
presence of fusion evidence, green line a neighborhood evidence, blue line a cooccurrence evidence, purple line 
an experimental evidence, yellow line a textmining evidence, light blue line a database evidence, and black line 
a coexpression evidence (see text for details).
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hydrolysis of Ran-GTP to Ran-GDP determines the release of the cargo from the 
export receptor. Following this action, XPO7 shows an iterative procedure returning 
to the nuclear compartment and mediate another round of transport.
The GWAS was also able to identify an additional putative gene, which is called 
glypican 1 (GPC1). GPC1 is located on chromosome 2q37.3 and has been replicated 
in an independent cohort of patients demonstrating heterozygous deletion of this 
gene as the sole gene in this region [62]. Glypicans are heparan sulfate proteogly-
cans. Glypicans are bound to the external surface of the plasmatic membrane of 
a cell by a glycosylphosphatidylinositol (GPI) linkage [62, 63, 66]. Homologs of 
glypican molecules have been identified throughout the Eumetazoa, although clear 
glypican homologs are not definitely found outside the Metazoa. The family of these 
proteoglycans includes six members (GPC1–GPC6). Glypican family members are 
tangled in numerous signaling and developmental pathways in hepatocytes and 
cholangiocytes, and there is role of GPC-3 for being a marker and a therapeutic target 
of hepatocellular carcinoma [66], In 2018, Sangkhathat et al. used a whole exome 
sequencing approach to look for other cholestasis entities in 20 cases diagnosed 
with BA in Thailand. These authors targeted well 19 genes associated with infantile 
cholestasis syndromes. Variant selection focused on those with allele frequencies 
in dbSNP150 database of less than 0.01. A polymerase chain reaction (PCR)-direct 
sequencing was used to verify all selected variants. Of the 20 cases studied, 13 rare 
variants were detected in nine genes: four in JAG1 (Alagille syndrome), two in 
MYO5B (progressive familial intrahepatic cholestasis [PFIC] type 6), and one each in 
ABCB11 (PFIC type 2), ABCC2 (Dubin-Johnson syndrome), ERCC4 (Fanconi ane-
mia), KCNH1 (Zimmermann-Laband syndrome), MLL2 (Kabuki syndrome), RFX6 
(Mitchell-Riley syndrome), and UG1A1 (Crigler-Najjar syndrome). The authors 
concluded that severe inflammatory cholangiopathy in BA might be a shared pathol-
ogy among several infantile cholestatic syndromes [34]. Although these results may 
be controversially discussed, there is time to verify these conclusions. However, far 
to be univocal the genetic research on BA showed that other genes involved in biliary 
tract dysmorphogenesis and cholestasis, the immunologic response, vasculogenesis, 
and left-right patterning might contribute to this disease with worrisome complica-
tions and prognosis. Currently, clinical investigations and nonhuman model systems 
are focusing on CFC1, CFTR, JAG1, IFN-γ, INV, MIF, VEGF, SOX17, and ZIC3 
[34–40, 65, 67]. Currently, the finalization of genomic studies has not been reached, 
but the application of GWAS points incontrovertibly toward two candidate genes that 
may underlie the development of BA in these patients, including ADD3 and GPC1. It 
may be important to cross the ethnics and investigate other populations. The use of 
next-generation sequencing (NGS) has been a throughput in technology in the last 
decade and will have enormous value in BA research. NGS technologies are miniatur-
ized and parallelized sequencing platforms are targeting from 1 million to 43 billion 
short reads (50–400 bases each) per instrument run. The massive parallel sequencing 
is carried out via spatially separated, clonally amplified DNA templates or single 
DNA molecules localized in a flow cell. NGS is different from the PCR-based Sanger 
sequencing that is based on polyacrylamide gel electrophoretic separation of chain-
termination products available in individual sequencing reactions. NGS strengths 
include the possibility to detect abnormalities across the entire genome, including 
substitutions, deletions, insertions, duplications, copy number changes (gene and 
exon), and chromosome inversions/translocations using less DNA than required for 
traditional DNA sequencing approaches (e.g., Sanger sequencing). NGS gives data 
on some molecular aberrations with no currently clinical significance. It requires 
sophisticated bioinformatics systems, fast data processing, and large data storage 
capabilities, which can be costly without adequate bioinformatics support. Despite 
drawbacks, NGS has been used extensively in research and diagnostics [68–72].
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5. Epigenetics and genetic modifiers of biliary atresia
Epigenetic modification (e.g., methylation) may be at the basis of some BA patients 
[73]. Epigenetics is the investigation of inherited variations in the expression of genes 
that do not involve deviations to the underlying DNA sequence. It means that there is a 
change in phenotype without evidence of a deviation in genotype. Epigenetics specifi-
cally affects how cells translate the genes. There is a natural occurrence of epigenetics, 
but several factors including age, lifestyle, environment, and disease state influence 
the epigenetic flow in an organism. Epigenetic changes can affect how cells terminally 
differentiate or how cancer can occur. There are at least three systems including DNA 
methylation, modification of histones, and non-coding RNA (ncRNA)-associated 
gene silencing that are considered to initiate and endure epigenetic change. Epigenetic 
studies in BA may be particularly challenging because hepatocyte or cholangiocyte 
DNA of patients may be needed. It has been hypothesized that some genes that are 
relevant for the biliary function may be involved. These genes may be A1AT, JAG1, and 
CFTR, but also targeting the bile canaliculus transporters [50, 74–77].
6. Non-genetic contributive factors of biliary atresia
It would be incomplete this chapter, if BA would not be discussed exploring the 
non-genetic causes of this condition. Although poorly understood, some non-genetic 
factors may contribute to the development of this surgically correctable neonatal 
biliary disease. There are several categories, including viruses, toxins, immunological 
dysregulations, and feto-maternal factors [1, 78–82]. Cytomegalovirus (CMV) is a 
genus of viruses in the order Herpesvirales, in the family Herpesviridae, in the subfamily 
Betaherpesvirinae. Both monkeys and humans serve as natural hosts and eight species 
in this genus are known. Among them, there is the human cytomegalovirus, which is 
the species that infects humans. CMV has been implicated in BA a few instances in the 
literature [83–91]. Challenges are the inconsistency of its detection in clinical samples 
or routine liver biopsy. Other viruses include rotavirus and reovirus, but also other 
viruses, such as hepatotropic viruses, have been questioned as etiologic factors for this 
obstructive cholangiopathy of the neonatal age [83, 92–103]. Another etiologic consid-
eration are toxins. Bush tea or other components containing pyrrolizidine alkaloids, 
deriving mostly from the Senecio species, Crotalaria species, Heliotropium lasiocarpum, 
or Symphytum (comfrey), are a known source to hepatologists and toxicologists [104]. 
Hepatotoxic pyrrolizidine alkaloids have been found in 150 species of plants. BA may 
be considered in analogy to the obliterative process seen in pyrrolizidine alkaloids or 
similar plants [105]. In Australia, toxins present in plants of the Dysphania species have 
been associated with a damage of the biliary system in animals, but the significance for 
humans is still uncertain [106, 107]. The incidence of viral infection is not epidemic, 
and BA does not occur outside of the perinatal period. Thus, a virologic etiology may 
not be widely supported by a strong evidence. An immune-related or an autoimmuno-
logic disorder is also still plausible due to the absence of recurrence after transplanta-
tion [50]. In some infants from Egypt, the cause of BA has been demonstrated to be 
result of aflatoxin-induced cholangiopathy acquired prenatally in infants who harbor 
glutathione S-transferase M1 deficiency [108].
7. Final remarks and future perspectives
BA remains a very challenging disease not only from the clinical point of views but 
also for the pathological one and transcriptome analysis cannot provide a univocal 
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answer [109]. The importance to differentiate surgically correctable cholangiopathies 
in the neonatal age is crucial for the prognosis of these patients. The introduction 
of the Kasai HPE has revolutionized the outcome of patients harboring this condi-
tion. The timing when the Kasai HPE is performed has been emphasized as critical. 
Alternatively, liver transplantation is the only hope for liver cirrhosis developed on the 
ground of a BA. The underlying cause(s) and outcome contributor(s) to BA remain 
poorly understood, but new technologies are on the front to target this field. Two 
genes that we currently consider of significant interest for BA are ADD3 gene and 
GPC1 gene. The feasibility of animal models may also be extremely used in studying 
the cohorts of animals that may develop this condition in prospective multigeneration 
investigations. The use of in-depth learning methodologies will be vital in analyzing 
the massive mole of data that can come out from these experiments, but the use of 
highly sophisticated computational platforms is opening the horizon for this disease.
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